Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Cynomolgus / Rhesus macaque CTLA-4 Protein, His Tag, 200µg  

Recombinant Cynomolgus / Rhesus macaque CTLA-4 Protein, His Tag, 200µg

Recombinant Cynomolgus / Rhesus macaque CTLA4 / CD152 Protein, Ala 37 - Ser 160, produced in human 293 cells (HEK293), His Tag (MALS verified)

Synonym
Recombinant Cynomolgus Protein, CTLA4, CD152, CELIAC3, GRD4, GSE, ICOS, IDDM12

More details

CT4-C5227-200

Availability: within 7 days

216,00 €

Background
CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.

Source
Recombinant Cynomolgus / Rhesus macaque CTLA-4, His Tag (CT4-C5227) is expressed from human 293 cells (HEK293). It contains AA Ala 37 - Ser 160 (Accession # G7PL88-1). In the region Ala 37 - Ser 160, the AA sequence of Cynomolgus and Rhesus macaque CTLA-4 are homologus.
Predicted N-terminus: Ala 37

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 14.1 kDa. The protein migrates as 19-24 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy"
Li, Wang, Lin et al
Front Med (2022)
(2) "Multiparameter Longitudinal Imaging of Immune Cell Activity in Chimeric Antigen Receptor T Cell and Checkpoint Blockade Therapies"
Xie, El Rami, Zhou et al
ACS Cent Sci (2022) 8 (5), 590-602
(3) "The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study"
Holmberg, Ny, Hieken et al
Eur J Cancer (2022)
Showing 1-3 of 11657 papers.